Lung Cancer / Mesothelioma
When I first started OncTalk, there was a lot of buzz about celebrex (celecoxib) as a cancer drug, but almost all of it was among patients talking about it on the internet: oncologists watching the field hadn’t been impressed by the early returns, including this one (despite the fact that some of my earliest work […]
2 CommentsMy presentation at the World Conference on Lung Cancer last week was on a trial I led for patients with previously treated advanced NSCLC, who received a combination of taxotere every three weeks along with a new drug called DN-101, or Asentar. It’s actually a new formulation of calcitriol, which stimulates the vitamin D receptor […]
1 CommentsLet’s move to combinations of velcade with other anti-cancer agents. My friend, Dr.Angela Davies from the University of California at Davis, led a single-arm phase II trial conducted by the Southwest Oncology Group, SWOG 0339, that evaluated the combination of velcade with gemcitabine and carboplatin (abstract here). A total of 114 patients previously untreated for advanced […]
6 CommentsA novel agent called motexafin gadolinium (MGd), with a marketed name of Xcytrin, has been studied as a potential neuroprotectant as well as radiosensitizer that may allow patients with brain metastases to do better when it as added to whole brain radiation therapy (WBRT) than they would with WBRT alone. It is a molecule […]
2 CommentsCelecoxib (Celebrex) has been studied in combination with chemo for NSCLC and has generated enough promising results to raise expectations but also enough negative data to produce disappointment. Dr. Altorki’s trial (abstract here) gave 29 patients with stage IIIA, resectable NSCLC celebrex at 400 mg by mouth twice daily (higher than standard arthritis dosing, but the dose […]
2 Comments We’ll break from brain metastases for a while to talk about another potential avenue of targeted therapy in lung cancer: the cyclo-oxygenase, or COX, pathway.
Cyclo-oxygenase (COX) inhibition has been studied as a potential mechanism for inhibiting cancer over the past few years, and recently some early clinical trial results have looked promising and […]
Posts
| Core Concepts
| Subject Archives
| Monthly Archives
| Resources
| 
Donate
| Forums
| GRACE Home
Disclaimer: The information provided at GRACE is for informational purposes only. The faculty of GRACE is not providing medical advice, diagnosis or treatment and cannot replace the medical advice of your doctor or health care provider. (Full Disclaimer)
© 2007-2008 GRACE. All rights reserved.
